Press Announcements > FDA approves first epoetin alfa biosimilar for the treatment of anemia

Press Announcements > FDA approves first epoetin alfa biosimilar for the treatment of anemia



FDA approves first epoetin alfa biosimilar for the treatment of anemia

The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. Continue reading.